home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

1.980 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

38 39 Next >

Stocks That Hit 52-Week Lows On Friday ↗

August 11, 2023

During the Friday's sesion, 157 stocks hit new 52-week lows.

Via Benzinga

Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

August 03, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Why Cassava Sciences Stock Is Trading Down Today ↗

July 05, 2023

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower Wednesday.

Via Benzinga

Why Shares of Cassava Sciences Are Dropping Wednesday ↗

July 05, 2023

The company announced phase 3 trial results for its lead Alzheimer's therapy.

Via The Motley Fool

Why Shares of Cassava Sciences Jumped This Week ↗

May 12, 2023

Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam.

Via The Motley Fool

Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now ↗

July 13, 2023

These three worst biotech stocks are not investable even if you're bullish on the sector overall. There are better options.

Via InvestorPlace

7 Biotech Stocks to Sell in July ↗

July 13, 2023

Running the gamut from large to small, and from commercial stage to clinical stage, these are seven top biotech stocks to sell in July.

Via InvestorPlace

FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline ↗

July 07, 2023

The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.

Via Benzinga

Stock Market Round-Up: Rivian Rides High, Meta Platforms Makes Moves, And Tesla Ticks Up ↗

July 05, 2023

Via Benzinga

Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results ↗

July 05, 2023

Cassava Sciences (SAVA) stock is down 11% on underwhelming results from its Phase 3 clinical trials for its Alzheimer's treatment.

Via InvestorPlace

Why Is Cassava Sciences (SAVA) Stock Up 15% Today? ↗

May 09, 2023

Today, shareholders in Cassava Sciences and SAVA stock are cheering some positive research data for its key drug candidate.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 05, 2023

Via Benzinga

Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 05, 2023

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in...

Via Benzinga

Dow, S&P 500 Move Lower On Renewed Fed Fatigue ↗

July 05, 2023

Stocks are moving lower ahead of the Federal Reserve's June meeting minutes, which are due out this afternoon.

Via Talk Markets

Promising Alzheimer's Treatment: Cassava Sciences' Simufilam Slows Cognitive Decline by 38% in Clinical Study ↗

July 05, 2023

Cassava Sciences Inc (NASDAQ: SAVA) announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus...

Via Benzinga

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

July 05, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

New Research Shows Simufilam Suppresses Overactive mTOR

June 27, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

New Publication Highlights Basic Science Supporting Simufilam

June 12, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Cassava Sciences to Present at the Jefferies Global Healthcare Conference

June 01, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

3 Biotech Stocks to Avoid Like the Plague ↗

May 23, 2023

Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

May 22, 2023

Via Benzinga

Hero or Zero? 7 High-Risk Stocks to Make You Rich… Or Broke. ↗

May 21, 2023

These seven high-risk stocks could ultimately rocket to the moon, or fall to the depths of the stock market graveyard.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 18, 2023

Via Benzinga

Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease

May 11, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Top 5 Health Care Stocks That May Collapse In Q2 ↗

May 10, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

May 08, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates

May 01, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference

April 26, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Short Interest Sector Focus: Healthcare Sector ↗

April 04, 2023

As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector...

Via Benzinga

Why Is Asana (ASAN) Stock Up 24% Today? ↗

March 09, 2023

Asana (ASAN) stock is on the rise Thursday as investors react to the CEO share purchase plans and its latest earnings report.

Via InvestorPlace

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com